Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
about
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving ConceptsAdherence to antiretroviral therapy: merging the clinical and social course of AIDS.Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort StudyHigh-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South AfricaComparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesPreparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills model.HIV epidemiology and the effects of antiviral therapy on long-term consequences.A pandemic of the poor: social disadvantage and the U.S. HIV epidemic.Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Improving adherence to antiretroviral treatment in Uganda with a low-resource facility-based intervention.Conspiracy beliefs about HIV are related to antiretroviral treatment nonadherence among african american men with HIV.Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trialSpiritual and mind-body beliefs as barriers and motivators to HIV-treatment decision-making and medication adherence? A qualitative studyAdherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.The interplay of sociodemographic factors on virologic suppression among a U.S. outpatient HIV clinic populationSelf-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.Factors informing HIV providers' decisions to start antiretroviral therapy for young people living with behaviorally acquired HIV.Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.Factors influencing adherence to antiretroviral treatment in Nepal: a mixed-methods studyRisk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.Reasons for ART non-adherence in the Deep South: adherence needs of a sample of HIV-positive patients in Mississippi.A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns.Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya.HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United StatesLow lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited settingAdherence to antiretroviral therapy (ART) among people living with HIV (PLHIV): a cross-sectional survey to measure in Lao PDR.Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adultsDirectly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance.A Fluctuating Pattern of Over- and Under-Adherence for HAART: A Case Study from a Videophone Intervention ProjectUse of Videophone Technology to Address Medication Adherence Issues in Persons with HIV.Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.Trauma, dissociation, and antiretroviral adherence among persons living with HIV/AIDS.Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapyFactors associated with utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, Georgia.Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected childrenDevelopment of an easy to use tool to assess HIV treatment readiness in adolescent clinical care settings.Patient and provider perspectives on cellular phone-based technology to improve HIV treatment adherence.Factors associated with non-adherence to highly active antiretroviral therapy in Nairobi, Kenya.
P2860
Q22241321-8863B04C-1552-419F-B375-8AC901D406A5Q24810599-C3929BB8-F25C-4D0E-872D-05B6BCBA23DBQ28534423-98A013BD-08C2-4662-8164-52EA73A18B0EQ28535483-C11F7629-9B26-43FC-A400-113110DC42B9Q28539169-F4C0C465-9C02-4800-8759-A9A8F56EEA43Q30227266-58F58C60-1175-466E-95F3-A5BFE894A6B8Q30372536-BCA91DBF-6F6B-4866-8622-95C29D377C42Q30430745-392729F2-CA03-4C8B-8A40-F976227C9B30Q33553259-D92A4ED1-E45A-4BED-87A1-27405D0E99E1Q33724247-CB48EA92-2740-46EA-A129-1BE9842C3E11Q33725057-46603F66-533D-493F-9B27-9752A9A73AD5Q33753905-8E2E7131-80D4-4C55-85B6-6A093E52ADC0Q33788103-6BDFF424-A987-4078-ACAC-D9EBA06D625FQ33797894-72A55EC7-94FA-49E1-82DD-E34910C25031Q33814942-AE27C2F9-083D-46A3-841A-5C147A60F1B4Q33827836-6479D8E0-8CC2-43C8-B99B-B46B228C8C6DQ33851716-15FC50E4-911C-4D47-AA2C-7AC68E01C163Q34084817-85AB6A80-E9F9-4BD2-902E-B50937968E01Q34226062-C5D176F8-6E00-494A-B636-5162E5D0E9E3Q34259994-4F7CC08A-5E9D-42E1-BA2B-558E25D85563Q34283336-7CF7A0A6-9FAE-4481-9217-31DDA43FD731Q34493306-1D255C3E-DDF0-4428-B03D-8EC743A58D01Q34573789-DF1E24DE-3BF4-4FD4-BC4A-59C673E50B95Q34577449-4E0EE580-6B00-4463-ABEB-20FD1519985FQ34598681-07F0FDCE-ED3D-42C3-9C59-46BD868AF837Q34643410-0BE8FB1D-3B94-4972-B047-1291D056487CQ34778123-C059EA4A-328B-4AB8-B321-809071B94D4DQ34786563-C638F49A-F6A2-47C5-AFFE-ED9BC65265B2Q34817650-433A9DB4-6B51-465D-AC84-743FBA646D98Q34875358-986D7A65-4159-4298-A21F-1364F1EAFE69Q34994459-A3A67151-782D-43BA-A71A-5591772E6FE8Q35008798-6E74C2CB-D459-4794-977A-8906B65CC7C9Q35033474-9A3A64EB-09BC-49BD-BAD9-217541D87A35Q35054354-DB4D31C7-4244-41D3-A2D8-31FFB0F9F43CQ35158051-7FF972EE-D90D-4766-8094-C6CAEFD8115AQ35174808-3CAAE253-DA55-480E-B7E2-8B36DE8457DFQ35371115-981D07F3-9E3A-46AB-9BE4-2C69156AC46DQ35470335-81ABD730-8423-42C6-802E-44F26497507AQ35564744-426ABF5D-DC8E-4EBB-A97D-1E90CAE8B0D9Q35639255-5D79AA16-0641-419C-81C8-4A7A2F6FB936
P2860
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@ast
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@en
type
label
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@ast
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@en
prefLabel
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@ast
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@en
P356
P1476
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy.
@en
P2093
Andrew R Moss
P304
P356
10.1093/JAC/DKH162
P407
P577
2004-03-24T00:00:00Z